Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA highlighting the role of exosomal RNA (exRNA) in head and neck cancers (HNCs).

How can we tell whether EGFR inhibitors effectively inhibit the key pathways driving EGFR-mediated radioresistance? Considering tumor instability and heterogeneity, how can we optimize the ...

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

Rapid eGFR decline occurred in 23% of patients on ... “Physical exercise is known to mitigate several of these pathways, preventing vascular diseases in the heart, brain and musculoskeletal ...

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release ...